Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib for Prurigo Nodularis
ChiCTR2600123006Phase 4Recruiting
- Sponsor
- Southern Medical University Dermatology Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivarmacitinib in prurigo nodularis (PN), sponsored by Southern Medical University Dermatology Hospital. Primary endpoint: Proportion of subjects with ≥4-point reduction in WI-NRS at Week 24. Started Apr 2026; status: recruiting.
02
Drugs
ivarmacitinib
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on ChiCTR2600123006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123006.